Clozapine-induced Hypersalivation - Feasibility Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 25, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

February 23, 2018

Conditions
Sialorrhea
Interventions
DRUG

Hyoscine

300 micrograms twice daily, increasing to 300 micrograms three times daily

DRUG

Glycopyrrolate

1 milligram twice daily, increasing to 1 milligram three times daily

OTHER

Placebo

Placebo twice daily, increasing to placebo three times daily

Trial Locations (2)

Unknown

Lancashire Care NHS Foundation Trust, Preston

Mersey Care NHS Trust, Liverpool

All Listed Sponsors
collaborator

University of Manchester

OTHER

collaborator

University of Central Lancashire

OTHER

collaborator

Manchester Mental Health & Social Care Trust

OTHER_GOV

collaborator

Lancashire Care NHS Foundation Trust

NETWORK

lead

Mersey Care NHS Trust

OTHER

NCT02613494 - Clozapine-induced Hypersalivation - Feasibility Trial | Biotech Hunter | Biotech Hunter